1
|
Kawada S, Tanimoto M, Onishi N, Takaishi A, Morita H. Successful use of lidocaine hydrochloride in the management of ventricular arrhythmias in a case of pilsicainide intoxication. HeartRhythm Case Rep 2024; 10:119-123. [PMID: 38404968 PMCID: PMC10885686 DOI: 10.1016/j.hrcr.2023.10.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2024] Open
Affiliation(s)
- Satoshi Kawada
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Masafumi Tanimoto
- Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa, Japan
| | - Nobuhiko Onishi
- Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa, Japan
| | - Atsushi Takaishi
- Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa, Japan
| | - Hiroshi Morita
- Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| |
Collapse
|
2
|
Suzuki Y, Matsui Y, Hirano Y, Kondo I, Nemoto T, Tanimoto M, Arai H. Relationships among Grip Strength Measurement, Response Time, and Frailty Criteria. J Frailty Aging 2023; 12:182-188. [PMID: 37493378 DOI: 10.14283/jfa.2023.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2023]
Abstract
BACKGROUND Muscle response in older adults is believed to decrease with maximal muscle strength, although it has not been adequately assessed; further, the relationship between frailty and muscle response remains unexamined. OBJECTIVES This study aimed to develop a practical method for measuring muscle response using grip strength in older adults and to clarify the relationship between frailty and grip strength response. DESIGN, SETTING, AND PARTICIPANTS We performed a cross-sectional, clinical, observational study. A total of 248 patients (94 men and 154 women, mean age: 78.2 years) who visited the outpatient unit in the Integrated Healthy Aging Clinic of our Hospital for the first time were enrolled. MEASUREMENTS Using a grip strength measuring device originally developed by us, we measured grip strength response indices, such as reaction time, time constant, rate of force development (response speed), and maximum grip strength. Grip strength response indices were compared among three groups (robust, pre-frail, and frail) according to the Fried and Kihon checklist assessments for frailty. RESULTS Based on Fried's assessment, marked differences were found between groups not only in maximal grip strength but also in response time and response speed. Based on the Kihon checklist assessment, there was no significant difference in response time; however, a considerable difference in response speed for the left hand was observed. Moreover, according to the Kihon checklist assessment, some cases showed differences in muscle response although not in maximal muscle strength. CONCLUSIONS The response speed of grip strength was suggested to decrease with frailty. The results suggest that measurement of grip strength response in both hands is useful to examine the relationship between frailty and grip strength response.
Collapse
Affiliation(s)
- Y Suzuki
- Yasuo Suzuki, 26-2 Higashihaemi-cho, Handa-city, Aichi, 475-0012, Japan, , Phone: +81-569-20-0112, Fax: +81-569-20-0127
| | | | | | | | | | | | | |
Collapse
|
3
|
Amioka N, Takaishi A, Nakamura K, Endo T, Iida T, Yamaji T, Mori H, Kishinoue T, Yasuhara K, Matsuo N, Tanimoto M, Nakano Y, Onishi N, Ueeda M, Ito H. Innovative clinical pathway shortened the length of hospital stay and prevented readmission in patients with acute decompensated heart failure. J Cardiol 2022; 80:232-239. [DOI: 10.1016/j.jjcc.2022.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 03/16/2022] [Accepted: 03/29/2022] [Indexed: 11/28/2022]
|
4
|
Takaishi A, Iida T, Kishinoue T, Mori H, Yamaji T, Tanimoto M, Onishi N, Hirohata S, Ueeda M, Ito H. Examination of the acute efficacy and safety about aggressive use of tolvaptan for early rising after admission in super-elder patients with congestive heart failure. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
From August 2015, for shortening of hospitalization period through efficient medical care in acute phase, we had introduced a unique clinical pathway (PATH) for congestive heart failure (CHF) cases. In PATH, since immediate taking of Tolvaptan, which is an strong oral diuretic and approver for use in the treatment of CHF cases since 2010 in Japan, after admission is specified, early diuresis makes it possible to achieve early rising from bed and streamline each medical care such as oxygen inhalation, continuous infusion, and urethral catheterization. Early rising from bed is particularly important for super-elder CHF patients who merge often frail. On the other hand, for super-elder CHF patients, it is feared that aggressive use of Tolvaptan may frequently cause dehydration, renal damage caused by it, or hypernatremia, which is a peculiar side effect about the drug.
Purpose
In this study, we examined the usefulness and safety of active use of Tolvaptan by introducing PATH in patients with super-elder CHF patients.
Methods
We set up three groups, NE group consist of 37 CHF cases (90 years old or over) who admitted in our hospital before (without) introduction of PATH between April 2014 and July 2015, PE group consist of 130 CHF cases (90 years old or over) and PY group consist of 466 CHF cases (under 90 years old) who ware admitted with introduction of PATH between August 2015 and July 2020. And in each group, we investigated various medical conditions in their acute phase after admission and the incidence of adverse events related to oral administration of tolvaptan, and examined the differences between three groups.
Results
Between NE group and PE group, there were no significant differences in mean age, pre-hospital living status, or clinical status at admission (Figure 1). But due to lean and efficient CHF care, the average length of hospitalization period was significantly shorter in PE group. And, in PE group, each medical care was performed as efficiently as in PY group, but the progression of renal damage or hypernatremia that required unscheduled discontinuation of tolvaptan use occurred more frequently in PE group (Figure 2).
Conclusions
Aggressive Tolvaptan use through our unique clinical pathway for congestive heart failure cases seemed to be useful even in super-elder patients. Although we thought that the safety of active use of tolvaptan for super-elder patients was well tolerated considering the results of this study, the incidence of adverse events such as hypernatremia was clearly higher in super-elder patients than in non-super-elder patients. It seemed that we should pay close attention to the clinical data of super-elder patients after introduction of tolvaptan.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
| | - T Iida
- Mitoyo General Hospital, Kanonji, Japan
| | | | - H Mori
- Mitoyo General Hospital, Kanonji, Japan
| | - T Yamaji
- Mitoyo General Hospital, Kanonji, Japan
| | | | - N Onishi
- Mitoyo General Hospital, Kanonji, Japan
| | - S Hirohata
- Okayama University, Graduate School of Health Sciences, Okayama, Japan
| | - M Ueeda
- Ueeda cardiovasculal clinic, Toyonaka, Japan
| | - H Ito
- Okayama University, Department of Cardiovascular Medicine, Okayama, Japan
| |
Collapse
|
5
|
Takaishi A, Iida T, Kishinoue T, Mori H, Yamaji T, Tanimoto M, Onishi N, Hirohata S, Ueeda M, Ito H. Examination about more realistic prognosis evaluation method, how long the patients with congestive heart failure can spend at home. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
From August 2015, for efficient medical care in congestive heart failure (CHF) cases, we had introduced a unique clinical pathway (PATH) provided the immediate use of Tolvaptan and comprehensive education by multi-disciplinary staff after admission. And by introduction of PATH, we confirmed the shortening effect of hospitalization period with CHF and the suppressive effect of readmission with CHF after discharge. But since almost CHF patients repeat hospitalization and discharge due to change of their medical condition, the investigation for only first readmission rate after discharge is not enough to assess the entire long clinical course of CHF. Recently we found one report about evaluation method for CHF clinical prognosis, how long CHF patients can stay healthy at their own home after discharge within a certain period. This evaluation method is considered to take into account the long clinical course of CHF.
Purpose
We investigated whether the CHF patients introduced PATH on admission could stay longer at their home than CHF patients without PATH.
Methods
Between April 2014 and July 2019, 471 CHF cases, who ware admitted in our hospital at first and could be followed up for at least 1 month after discharge, ware enrolled. We divided them to two groups, PATH- group before introducing PATH (until July 2015, 142 cases), and PATH+ group applied PATH (after August 2015, 329 cases). Between both groups, we investigated the readmission rate (RR) with CHF and the total period (TP) that patients could spend at home within1, 3, 6 and 12month after discharge.
Results
There were no significant differences in mean age, pre-hospital living status, or clinical status at admission between the two groups. On the other hand, due to efficient CHF care, the average length of hospital stay was significantly shorter (figure1). RR within 1, 3, 6 and 12 months after discharge ware all lower in PATH+ group. And TP within 1, 3, 6 and 12 months after discharge ware all longer in PATH+ group (figure2).
Conclusion
By introducing our unique clinical pathway for congestive heart failure cases requiring hospitalization, we could confirm not only the improvement of their conventional clinical prognosis index but also the improvement of their new and more realistic clinical prognosis index after discharge.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
| | - T Iida
- Mitoyo General Hospital, Kanonji, Japan
| | | | - H Mori
- Mitoyo General Hospital, Kanonji, Japan
| | - T Yamaji
- Mitoyo General Hospital, Kanonji, Japan
| | | | - N Onishi
- Mitoyo General Hospital, Kanonji, Japan
| | - S Hirohata
- Okayama University, Graduate School of Health Sciences, Okayama, Japan
| | - M Ueeda
- Ueeda cardiovasculal clinic, Toyonaka, Japan
| | - H Ito
- Okayama University, Department of Cardiovascular Medicine, Okayama, Japan
| |
Collapse
|
6
|
Matsuo N, Miyoshi T, Takaishi A, Kishinoue T, Yasuhara K, Tanimoto M, Nakano Y, Onishi N, Ueeda M, Ito H. High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction. Nutrients 2021; 13:nu13020371. [PMID: 33530352 PMCID: PMC7911271 DOI: 10.3390/nu13020371] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 01/21/2021] [Accepted: 01/22/2021] [Indexed: 12/31/2022] Open
Abstract
The clinical relevance of polyunsaturated fatty acids (PUFAs) in heart failure remains unclear. The aim of this study was to investigate the association between PUFA levels and the prognosis of patients with heart failure with preserved ejection fraction (HFpEF). This retrospective study included 140 hospitalized patients with acute decompensated HFpEF (median age 84.0 years, 42.9% men). The patients' nutritional status was assessed, using the geriatric nutritional risk index (GNRI), and their plasma levels of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (AA), and dihomo-gamma-linolenic acid (DGLA) were measured before discharge. The primary outcome was all-cause mortality. During a median follow-up of 23.3 months, the primary outcome occurred in 37 patients (26.4%). A Kaplan-Meier analysis showed that lower DHA and DGLA levels, but not EPA or AA levels, were significantly associated with an increase in all-cause death (log-rank; p < 0.001 and p = 0.040, respectively). A multivariate Cox regression analysis also revealed that DHA levels were significantly associated with the incidence of all-cause death (HR: 0.16, 95% CI: 0.06-0.44, p = 0.001), independent of the GNRI. Our results suggest that low plasma DHA levels may be a useful predictor of all-cause mortality and potential therapeutic target in patients with acute decompensated HFpEF.
Collapse
Affiliation(s)
- Naoaki Matsuo
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; (N.M.); (H.I.)
| | - Toru Miyoshi
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; (N.M.); (H.I.)
- Correspondence: ; Tel.: +81-86-235-7351
| | - Atsushi Takaishi
- Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa 769-1601, Japan; (A.T.); (T.K.); (K.Y.); (M.T.); (N.O.)
| | - Takao Kishinoue
- Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa 769-1601, Japan; (A.T.); (T.K.); (K.Y.); (M.T.); (N.O.)
| | - Kentaro Yasuhara
- Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa 769-1601, Japan; (A.T.); (T.K.); (K.Y.); (M.T.); (N.O.)
| | - Masafumi Tanimoto
- Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa 769-1601, Japan; (A.T.); (T.K.); (K.Y.); (M.T.); (N.O.)
| | - Yukari Nakano
- Nakano Cardiovascular Clinic, Kagawa 762-0012, Japan;
| | - Nobuhiko Onishi
- Department of Cardiovascular Medicine, Mitoyo General Hospital, Kagawa 769-1601, Japan; (A.T.); (T.K.); (K.Y.); (M.T.); (N.O.)
| | | | - Hiroshi Ito
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; (N.M.); (H.I.)
| |
Collapse
|
7
|
Takaishi A, Kisinoue T, Mori H, Yoshino T, Yamaji T, Yasuhara K, Tanimoto M, Kagawa K, Onishi N, Imai M, Ueeda M. Our unique clinical pathway for congestive heart failure cases required admission achieved a dramatic reduction of their hospitalization period and a significant reduction of readmission with heart fa. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
In recent years, the number of elderly congestive heart failure (CHF) cases has been increasing in Japan with the aging of the population. This tendency is particularly remarkable in rural areas where our facilities are located. After admission with CHF, the hospitalization period (PE) was prolonged due to various complications unique to the elderly, and re-exacerbation of CHF occurred shortly after discharge. Approximately 30% of them were readmitted within one year. From August 2015, for shortening of PE and reduction of CHF readmission through the efficiency of CHF treatment and comprehensive patient education, we had introduced a unique clinical pathway (PATH) that provided the immediate use of Tolvaptan and comprehensive education by multi-disciplinary staff after admission.
Purpose
In this study, we verified whether the improvement of clinical prognosis were achieved by introduction of PATH.
Methods
Between April 2014 and July 2019, 635 CHF cases (764 admissions) ware enrolled. We divided them to two groups, N-group before introducing PATH (198 cases, 262 admissions) and P-group applied PATH (437 cases, 502 admission). Between both groups, we compared the various acute care situation, PE and readmission rate with CHF within 1 year after discharge.
Results
There were no differences between P and N-group in mean age, distribution of underlying illness or daily activity level before admission. There ware not also differences about left ventricle function by echocardiography and various blood test data at admission. The enforcement rate of continuous infusion and the rate of urinary catheter placement were significantly lower in the P-group (71 vs 88%; p<0.0001, 52 vs 63%; p<0.01, respectively). And their enforcement duration was significantly shorter in P-group (4.6±5.3 vs 10.5±9.6 days; p<0.0001, 6.3±7.9 vs 12.8±13.1 days; p<0.0001 respectively). The enforcement rate of cardiac rehabilitation was significantly higher in group P (94 vs 84%; p<0.0001), and the starting time of rehabilitation was significantly earlier (2.9±1.5 vs 6.3±4.8th illness day; p<0.0001). As a result, the average HP was significantly shorter in group P (16.5±13.4 vs 28.6±24.1 days, p<0.0001). The readmission rate with CHF within one year after discharge was significantly lower in group P (23 vs 36%; p<0.001).
Conclusion
By the introduction of our original clinical pathway for congestive heart failure, the efficiency of medical care was achieved and the mean hospitalization period was widely shortened. In addition, by the through comprehensive patient education by multi-disciplinary staff involved in the pathway, the self-restraint life style after discharge seemed to be maintained and the readmission with worsening of heart failure was significantly suppressed.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | | | - H Mori
- Mitoyo General Hospital, Kanonji, Japan
| | - T Yoshino
- Mitoyo General Hospital, Kanonji, Japan
| | - T Yamaji
- Mitoyo General Hospital, Kanonji, Japan
| | | | | | - K Kagawa
- Mitoyo General Hospital, Kanonji, Japan
| | - N Onishi
- Mitoyo General Hospital, Kanonji, Japan
| | - M Imai
- Mitoyo General Hospital, Kanonji, Japan
| | - M Ueeda
- Ueeda cardiovasculal clinic, Toyonaka, Japan
| |
Collapse
|
8
|
Matsuo N, Hayashi K, Katou Y, Hasegawa M, Tanimoto M, Fujiwara T, Kagawa K, Nakano Y, Oonishi N, Takaishi A, Hirohata S, Ueeda M. The westernization of life style and atherosclerosis in Japan – the balance of EPA and AA. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
9
|
Matsuo N, Hayashi K, Katou Y, Hasegawa M, Tanimoto M, Fujiwara T, Kagawa K, Nakano Y, Oonishi N, Takaishi A, Hirohata S, Ueeda M. Supplementation of Omega-3 PUFAs could improve long term prognosis after pci in patients without hyperlipidemia and diabetes. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.206] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
10
|
Pongpipatpaiboon K, Kondo I, Onogi K, Mori S, Ozaki K, Osawa A, Matsuo H, Itoh N, Tanimoto M. Preliminary Study on Prevalence and Associated Factors with Sarcopenia in a Geriatric Hospitalized Rehabilitation Setting. J Frailty Aging 2018; 7:47-50. [PMID: 29412442 DOI: 10.14283/jfa.2017.40] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The reported prevalence of sarcopenia has shown a wide range, crucially based on the diagnostic criteria and setting. This cross-sectional study evaluated the prevalence of sarcopenia and sought to identify factors associated with sarcopenia on admission in a specialized geriatric rehabilitation setting based on the newly developed the Asian Working Group for Sarcopenia algorithm. Among 87 participants (mean age, 76.05 ± 7.57 years), 35 (40.2%) were classified as showing sarcopenia on admission. Prevalence was high, particularly among participants ≥80 years old, with tendencies toward lower body mass index, smoking habit, lower cognitive function, and greater functional impairment compared with the non-sarcopenic group. Identification of sarcopenia in elderly patients before rehabilitation and consideration of risk factors may prove helpful in achieving rehabilitation outcomes.
Collapse
Affiliation(s)
- K Pongpipatpaiboon
- Izumi Kondo, Department of Rehabilitation Medicine, National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology (NCGG), 7-430 Morioka-cho, Obu City, Aichi Prefecture, Japan, Fax: +81-562-44-8518, Phone: +81-562-46-2311, E-mail:
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Eastell R, Dijk DJ, Small M, Greenwood A, Sharpe J, Yamada H, Yuba M, Tanimoto M, Deacon S. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial. Osteoporos Int 2016; 27:309-18. [PMID: 26446770 PMCID: PMC4715857 DOI: 10.1007/s00198-015-3342-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Accepted: 09/24/2015] [Indexed: 12/31/2022]
Abstract
UNLABELLED The cathepsin K inhibitor, ONO-5334, improves bone mineral density in postmenopausal women with osteoporosis. The effects of morning versus evening administration of ONO-5334 were investigated by measuring bone turnover marker levels in healthy postmenopausal women. Morning administration of ONO-5334 showed a more consistent suppressive effect on bone resorption than evening administration. INTRODUCTION Bone turnover is thought to be subject to circadian variation, and the efficacy of osteoporosis treatments may be optimized by regulating the time of dosing. This study assessed whether evening administration of the cathepsin K inhibitor, ONO-5334, had a differential effect on the bone turnover marker, C-terminal telopeptide of type I collagen (CTX-I), compared with morning administration. METHODS This was a single-center, single blind crossover study. Fourteen healthy postmenopausal women were assigned to receive ONO-5334 150 mg once daily for 5 days in each period; they were randomized to receive either evening doses in the first period and morning doses in the second or vice versa. Serum and urinary levels of CTX-I were measured throughout the study. RESULTS Both regimens showed similar patterns of reduction in serum and urinary CTX-I; however, CTX-I suppression was more consistently >60% over 24 h following morning administration. Morning administration led to 6% greater suppression of 24-h serum CTX-I area under the effect curve (AUE; 69 vs 63%; P < .05) and 7% greater suppression of urinary CTX-I/creatinine AUE (93 vs 86%; P < .01) than evening administration. Higher plasma ONO-5334 concentrations were observed between 12 and 24 h postdose following morning administration, with mean trough concentrations for the morning and evening regimens at 9.4 and 4.0 ng/mL, respectively. There were no safety findings of concern. CONCLUSION Morning dosing of ONO-5334 is more efficacious at reducing markers of bone turnover in healthy postmenopausal women than evening dosing. TRIAL REGISTRATION ClinicalTrials.gov: NCT01384188 , registered on June 27, 2011 EudraCT: 2008-006284-37.
Collapse
Affiliation(s)
- R Eastell
- Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK.
- Metabolic Bone Centre, Northern General Hospital, Herries Road, Sheffield, South Yorkshire, S5 7AU, UK.
| | - D-J Dijk
- Surrey Clinical Research Centre, University of Surrey, Guildford, UK
| | - M Small
- Ono Pharma UK Ltd, London, UK
| | - A Greenwood
- Surrey Clinical Research Centre, University of Surrey, Guildford, UK
| | | | | | - M Yuba
- Ono Pharmaceutical Co., Ltd, Osaka, Japan
| | - M Tanimoto
- Ono Pharmaceutical Co., Ltd, Osaka, Japan
| | | |
Collapse
|
12
|
Bessho A, Hosokawa S, Hotta K, Kudo K, Nogami N, Kuyama S, Gemba K, Inoue K, Okada T, Takigawa N, Tanimoto M, Kiura K. 453P Development of skin rash within the first week is a potential surrogate marker of effect in afatinib for EGFR mutant NSCLC: Okayama Lung Cancer Study Group Experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Minami D, Kubo T, Sato A, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K. 2PD Crizotinib could overcome acquired resistance to alectinib caused by HGF autocrine in ALK rearranged non-small cell lung cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv517.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Sakuragi S, Ichikawa K, Yamada K, Tanimoto M, Miki T, Otsuka H, Yamamoto K, Kawamoto K, Katayama Y, Tanakaya M, Ito H. An increase in the coronary calcification score is associated with an increased risk of heart failure in patients without a history of coronary artery disease. J Cardiol 2015; 67:358-64. [PMID: 26254962 DOI: 10.1016/j.jjcc.2015.06.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Revised: 06/21/2015] [Accepted: 06/26/2015] [Indexed: 11/26/2022]
Abstract
BACKGROUND The presence of coronary artery calcification (CAC) and its severity predict future cardiovascular events and is used for risk stratification. However, the association of CAC with heart failure (HF) in patients without a history of coronary artery disease (CAD) remains unclear. This study aimed to determine the correlations of CAC with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and HF events in patients without a history of CAD or HF. METHODS From June 2010 to June 2013, a total of 487 patients without a history of CAD and HF were enrolled. All of the patients underwent plane multi-detector computed tomography. They were divided into four categories according to CAC scores: ≤10, 11-100, 101-400, and ≥401. RESULTS The proportion of patients with high NT-proBNP levels increased with CAC categories (p<0.0001). The CAC score was associated with NT-proBNP levels ≥400pg/ml, with an odds ratio of 2.901 (95% confidence interval: 1.368-6.151, p=0.0055) for CAC scores ≥401 compared with CAC scores of 0-10 after adjustment for confounding factors. During the follow-up period of 497±315 days, nine patients were admitted for HF. Kaplan-Meier analysis showed that patients with CAC scores ≥401 had a lower rate of freedom from admission for HF with cumulative incidences of 0.4%, 1%, 2%, and 8% for CAC scores of 0-10, 11-100, 101-400, and ≥401, respectively (p<0.0001). Increasing CAC scores were associated with an increase in incidence of admission for HF, with a hazard ratio of 10.371 for CAC scores ≥401 (95% CI: 1.062-101.309, p=0.0443) compared with CAC scores of 0-10 after adjustment for risk factors. CONCLUSION Severe CAC is an independent determinant of high NT-proBNP levels and a predictor of admission for HF in a population without a history of CAD or HF.
Collapse
Affiliation(s)
- Satoru Sakuragi
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan.
| | - Keishi Ichikawa
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Keiji Yamada
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Masafumi Tanimoto
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Takashi Miki
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Hiroaki Otsuka
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Kazuhiko Yamamoto
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Kenji Kawamoto
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Yusuke Katayama
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Machiko Tanakaya
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Hiroshi Ito
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medical and Dentistry, Okayama, Japan
| |
Collapse
|
15
|
Sakuragi S, Ichikawa K, Yamada K, Tanimoto M, Miki T, Otsuka H, Yamamoto K, Kawamoto K, Katayama Y, Tanakaya M, Ito H. Serum cystatin C level is associated with left atrial enlargement, left ventricular hypertrophy and impaired left ventricular relaxation in patients with stage 2 or 3 chronic kidney disease. Int J Cardiol 2015; 190:287-92. [PMID: 25932809 DOI: 10.1016/j.ijcard.2015.04.189] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2015] [Revised: 04/21/2015] [Accepted: 04/22/2015] [Indexed: 01/15/2023]
Abstract
BACKGROUND Cystatin C is an endogenous marker of kidney function that overcomes the limitations of serum creatinine. High serum cystatin C levels have been associated with increased cardiovascular mortality and morbidity. In this cross-sectional study, we aimed to determine the associations between serum cystatin C levels and structural and functional cardiac changes in patients with stage 2 or 3 chronic kidney disease (CKD). METHODS AND RESULTS We enrolled 429 consecutive patients (aged 24-97 years) with CKD stage 2 or 3 and left ventricular (LV) ejection fraction (LVEF)>40%. Echocardiographic parameters, including LV mass index (LVMI), early diastolic mitral annulus velocity (e' velocity), left atrial volume index (LAVI), and N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) were measured. Patients were categorized into quartiles according to serum cystatin C levels. Cystatin C was associated with LAVI (p=0.0055), LVEF (p=0.0432), LVMI (p=0.0409), e' (p=0.0051), E/e' (p=0.0027), and log-transformed NT-proBNP (p<0.0001) according to multivariate linear regression analysis, after adjustment for confounding factors including creatinine-based estimated glomerular filtration rate (eGFRcreat) and urinary albumin to creatinine ratio. Incidence of eccentric and concentric hypertrophy increased with increasing cystatin C (Q1, 38%; Q2 49%; Q3, 51%; Q4, 66%, p=0.0008), mainly because of increasing concentric hypertrophy (Q1, 30%; Q2, 39%; Q3, 39%; Q4, 51%, p=0.0187). CONCLUSION A high serum cystatin C is strongly associated with structural cardiac abnormalities such as LVH and left atrial enlargement, impaired LV relaxation, and an increased NT-proBNP, independently of eGFRcreat in patients with stage 2 or 3 CKD.
Collapse
Affiliation(s)
- Satoru Sakuragi
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan.
| | - Keishi Ichikawa
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Keiji Yamada
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Masafumi Tanimoto
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Takashi Miki
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Hiroaki Otsuka
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Kazuhiko Yamamoto
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Kenji Kawamoto
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Yusuke Katayama
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Machiko Tanakaya
- Department of Cardiovascular Medicine, Iwakuni Clinical Center, Iwakuni, Japan
| | - Hiroshi Ito
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medical and Dentistry, Okayama, Japan
| |
Collapse
|
16
|
Kato Y, Ohashi K, Ichihara E, Isozaki H, Kudo K, Minami D, Kubo T, Sato A, Hotta K, Tabata M, Takigawa N, Tanimoto M, Kiura K. Epidermal Growth Factor Receptor Signaling Conferred Acquired Crizotinib Resistance to a Non-Small Cell Lung Cancer Cell Line Harboring the Slc34A2-Ros1 Fusion Gene. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu325.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Nogami N, Ichihara E, Kozuki T, Kubo T, Kishino D, Kuyama S, Bessho A, Fujii M, Takigawa N, Chikamori K, Aoe K, Nagata T, Fujimoto N, Hosokawa S, Harita S, Kamei H, Ueoka H, Hotta K, Tanimoto M, Kiura K. A Phase Ii Trial of Gefitinib in Combination with Bevacizumab As First-Line Therapy for Advanced Non-Small-Cell Lung Cancer with Activating Egfr Gene Mutations: Olcsg 1001. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Isozaki H, Ichihara E, Ohashi K, Ochi N, Yasugi M, Kubo T, Minami D, Yamane H, Sato A, Kudo K, Kato Y, Hotta K, Takigawa N, Sendo T, Tanimoto M, Kiura K. Acquired Resistance to a New Alk Inhibitor, Alectinib in Lung Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Kawasaki Y, Isoda H, Tanimoto M, Dosako S, Idota T, Ahiko K. Inhibition by Lactoferrin andκ-Casein Glycomacropeptide of Binding ofCholeraToxin to its Receptor. Biosci Biotechnol Biochem 2014; 56:195-8. [PMID: 1368296 DOI: 10.1271/bbb.56.195] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Inhibition from binding of Cholera toxin (CT) to Chinese hamster ovary (CHO)-K1 cells and ganglioside GM1 by lactoferrin (Lf) and kappa-casein glycomacropeptide (GMP) from cow's milk was examined. Both Lf and GMP effectively reduced the CT-derived morphological changes in CHO-K1 cells. The competitive binding assay demonstrated that both Lf and GMP inhibited the binding of CT to GM1, although their affinity for CT was lower than that of GM1. The inhibitory effect of Lf and GMP seemed to be attributed to their terminal sialic acid, although the sugar chain sequence only partially fitted to the CT-receptor.
Collapse
Affiliation(s)
- Y Kawasaki
- Technical Research Institute, Snow Brand Milk Products Co., Ltd., Kawagoe, Japan
| | | | | | | | | | | |
Collapse
|
20
|
Abstract
A droplet of an oil-in-water emulsion of methyl linoleate in a saccharide or protein solution that contained with a surfactant, a stabilizer, or both was dehydrated by drying equipment for a single droplet that resembled a spray drier. The lipid exposed on the surface of dehydated samples was extracted and measured by gas chromatography. Gum arabic or gelatin without additives resulted in little lipid being exposed; they were good entrapping agents. Little lipid was exposed with a pullulan solution containing lecithin, sugar ester, carboxymethylcellulose, or sodium caseinate but much was exposed with a maltodextrin solution containing any of the surfactants tested. When both the surfactant lecithin and the stabilizer xanthan gum were added to the emulsion prepared in a maltodextrin solution, lipid was not detected. The results suggested that effective entrapping agents of liquid lipids cause much emulsification, stabilize the emulsion (that is, they cause the continuous phase to be very viscous), and create a dehydrated matrix of fine, dense network layers.
Collapse
Affiliation(s)
- J Imagi
- Department of Food Science and Technology, Faculty of Agriculture, Kyoto University, Japan
| | | | | | | | | |
Collapse
|
21
|
Miki T, Sakuragi S, Yamada K, Tanimoto M, Fujiwara T, Otsuka H, Yamamoto K, Kawamoto K, Tanakaya M, Katayama Y. TCTAP A-189 The Prognostic Value of Coronary Artery Calcium Scoring for Future Coronary Artery Events in Patients with Chronic Kidney Disease. J Am Coll Cardiol 2014. [DOI: 10.1016/j.jacc.2014.02.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Minami D, Takigawa N, Hayakawa H, Mizuta M, Kudo K, Uchida K, Ichihara E, Sato A, Hotta K, Tabata M, Tanimoto M, Kiura K. Usefulness of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in Distinguishing Sarcoidosis from Recurrent Cancer in Patients with Lymphadenopathy after Surgery. Jpn J Clin Oncol 2013; 43:1110-1114. [DOI: 10.1093/jjco/hyt123] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
23
|
Otsuka H, Sakuragi S, Yamada K, Tanimoto M, Fujiwara T, Miki T, Yamamoto K, Kawamoto K, Katayama Y, Tanakaya M. High Sensitivity Cardiac Troponin T Reflects Presence of Left Ventricular Hypertrophy and Diastolic Dysfunction and Predicts Incidence of Cardiac Events. J Card Fail 2013. [DOI: 10.1016/j.cardfail.2013.08.449] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S, Ikeda Y, Nakahata T, Imamura M, Kawa K, Kato S, Tanimoto M, Kanda Y, Tanosaki R, Shiobara S, Kim SW, Nagafuji K, Hino M, Miyamura K, Suzuki R, Hamajima N, Fukushima M, Tamakoshi A, Halter J, Schmitz N, Niederwieser D, Gratwohl A. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transplant 2013; 49:195-200. [PMID: 24076552 DOI: 10.1038/bmt.2013.147] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2012] [Revised: 07/26/2013] [Accepted: 07/31/2013] [Indexed: 12/25/2022]
Abstract
Severe adverse events (SAE) and late hematological malignancies have been reported after PBSC donation. No prospective data on incidence and risk factors have been available for family donors so far. The Japan Society for Hematopoietic Cell Transplantation (JSHCT) introduced therefore in 2000 a mandatory registration system. It defined standards for donor eligibility and asked harvest centers to report any SAE immediately. All donors were examined at day 30 and were to be contacted once each year for a period of 5 years. Acute SAEs within day 30 were reported from 47/3264 donations (1.44%) with 14 events considered as unexpected and severe (0.58%). No donor died within 30 days. Late SAEs were reported from 39/1708 donors (2.3%). The incidence of acute SAEs was significantly higher among donors not matching the JSHCT standards (P=0.0023). Late hematological malignancies in PBSC donors were not different compared with a retrospective cohort of BM donors (N:1/1708 vs N:2/5921; P=0.53). In conclusion, acute and late SAEs do occur in PBSC donors at relatively low frequency but risk factors can be defined.
Collapse
|
25
|
Nogami N, Kozuki T, Segawa Y, Shinkai T, Maeda T, Ueoka H, Harita S, Kuyama S, Hosokawa S, Gemba K, Takemoto M, Takigawa N, Tabata M, Tanimoto M, Kiura K. A Phase II Study of Cisplatin (P), S-1 (S) and Concurrent Thoracic Radiotherapy (TRT) for Locally Advanced Non-Small-Cell Lung Cancer (LA-NSCLC): Okayama Lung Cancer Study Group Trial 0501. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32313-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
26
|
Kato Y, Ichihara E, Hotta K, Hisamoto A, Takigawa N, Nogami N, Kozuki T, Kudo K, Tabata M, Shinkai T, Tanimoto M, Kiura K. Difference in Incidence and Pattern of Salvage Treatment After Failure to 1ST-Line EGFR-TKI Therapy and Standard Cytotoxic Chemotherapy in Patients with EGFR-Mutant Advanced NSCLC: Okayama Lung Cancer Study Group Experience. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32321-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
27
|
Nishiyama A, Yoshioka H, Kunimasa K, Hotta K, Nogami N, Kozuki T, Harita S, Takigawa N, Tanimoto M, Kiura K. A Phase II Trial of Cisplatin-Docetaxel-Bevacizmab Induction Chemotherapy Followed by Bevacizmab and Pemetrexed Maintenance Therapy in Patients with Nonsquamous Cell Lung Carcinoma: Okayama Lung Cancer Study Group Trial 0903. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33788-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
28
|
Umemura S, Kiura K, Tsubouchi K, Takigawa N, Fujiwara K, Horita N, Segawa Y, Hamada N, Takata I, Tanimoto M. Clinical outcome of patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Kiura K, Takigawa N, Matsuo K, Kuyama S, Hosokawa S, Fujiwara K, Hisamoto A, Kozuki T, Ueoka H, Tanimoto M. Long-term follow-up of phase III trial of docetaxel and cisplatin (DP) versus mitomycin, vindesine, and cisplatin (MVP) with concurrent thoracic radiation therapy (TRT) for locally advanced non-small cell lung cancer (OLCSG 0007). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Hotta K, Kiura K, Suzuki E, Takigawa N, Fujiwara Y, Ichihara E, Tabata M, Tanimoto M. Influence of crossover therapy on the association between progression-free survival (PFS) and overall survival (OS) in randomized trials of molecular-targeted agents for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Fujiwara Y, Hotta K, Kiura K, Ochi N, Takigawa N, Oze I, Ichihara E, Tabata M, Tanimoto M. Time trend in treatment-related deaths of patients with small cell lung cancer (SCLC) enrolled into phase III trials of systemic treatment. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e17520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Hirata T, Yonemori K, Hirakawa A, Shimizu C, Tamura K, Ando M, Katsumata N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. Eur Respir J 2011; 38:1425-30. [DOI: 10.1183/09031936.00171610] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
33
|
Yamasuji Y, Nishimori H, Fujii M, Sugiyama H, Kobayashi K, Kadohisa S, Kondo E, Shinagawa K, Mominoki K, Kanekura T, Tanimoto M, Maeda Y. Prevention of Idiopathic Pneumonia Syndrome by Intra-bone Marrow Injection of Donor Cells. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Nishinohara M, Kobayashi K, Maeda Y, Shinagawa K, Tanimoto M. Affect of Cardiac Complications After Allogeneic Hematopoietic Stem Cell Transplantation From Various Stem Cell Sources. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
35
|
Fujii N, Hara Y, Nishinohara M, Kondo E, Maeda Y, Shinagawa K, Tanimoto M. Bronchiolitis Obliterans Syndrome After Hematopoietic Stem Cell Transplantation: Analysis of Single Center Experience. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Fujiwara Y, Hotta K, Di Maio M, Kiura K, Takigawa N, Tabata M, Tanimoto M. Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. Ann Oncol 2010; 22:376-82. [PMID: 20699278 DOI: 10.1093/annonc/mdq360] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
PURPOSE Despite recent improvements in supportive care, treatment-related death (TRD) remains a serious problem for lung cancer patients undergoing systemic chemotherapy. However, few studies have formally assessed possible changes in the TRD rate over the past two decades. PATIENTS AND METHODS We searched phase III trials to address the role of systemic treatment of advanced non-small-cell lung cancer (NSCLC). Time trend was assessed using linear regression analysis. RESULTS The overall incidence of TRD was calculated from 119 trials including 263 chemotherapy arms (46 477 patients), with information about the causes of deaths available for 197 arms (75%, 30 147 patients). Cisplatin-based regimens were the most frequently investigated. The crude TRD rate in the overall cohort of 119 trials was 1.26% and has been notably consistent over the investigated time (P = 0.762). The most common cause of death was febrile neutropenia, with no significant change in its incidence over the years (P = 0.139). In contrast, deaths due to renal toxicity decreased significantly (P = 0.042), whereas deaths due to pulmonary disorder increased significantly (P = 0.007). Among the pharmacological agents investigated, docetaxel (Taxotere) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were associated with relatively high rates of deaths from pulmonary disorders, but EGFR-TKIs were not associated with death from any other cause. CONCLUSIONS Despite of potential confounders in our results, the overall TRD rate has remained low, but not negligible, in phase III trials for advanced NSCLC, over the past two decades. Notably, the incidence and pattern of TRD stratified by cause have changed considerably.
Collapse
Affiliation(s)
- Y Fujiwara
- Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
| | | | | | | | | | | | | |
Collapse
|
37
|
Sonoyama T, Tani H, Matsuda K, Kageyama B, Tanimoto M, Kobayashi K, Yagi S, Kyotani H, Mitsushima K. Production of 2-Keto-l-Gulonic Acid from d-Glucose by Two-Stage Fermentation. Appl Environ Microbiol 2010; 43:1064-9. [PMID: 16346005 PMCID: PMC244186 DOI: 10.1128/aem.43.5.1064-1069.1982] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A practical method for the production of calcium 2-keto-l-gulonate (an intermediate in the Reichstein synthesis of l-ascorbic acid) from d-glucose has been established by using a two-stage fermentation system. d-Glucose was first converted to calcium 2,5-diketo-d-gluconate by a mutant strain of Erwinia sp. in a medium containing d-glucose, corn steep liquor, (NH(4))(2)HPO(4), and CaCO(3). After a 26-h cultivation, 328.6 mg of calcium 2,5-diketo-d-gluconate per ml was obtained, with a 94.5% yield from d-glucose. This broth was used directly for the next conversion without removal of cells by treatment with sodium dodecyl sulfate. The stereospecific reduction of calcium 2,5-diketo-d-gluconate to calcium 2-keto-l-gulonate was performed with a mutant strain of Corynebacterium sp. When the cell growth reached a maximum (about 16 h) in a medium containing d-glucose, corn steep liquor, NaNO(3), KH(2)PO(4), and trace elements, NaNO(3) was added to the culture, and then the calcium 2,5-diketo-d-gluconate broth was fed over a period of about 50 h. Since the mutant strain requires a hydrogen donor for reduction, the calcium 2,5-diketo-d-gluconate broth was mixed with d-glucose before being fed. The results of four two-stage fermentations in 10-m conventional fermentors showed that an average of 106.3 mg of calcium 2-keto-l-gulonate per ml was obtained, with a 84.6% yield from d-glucose, the starting material of calcium 2,5-diketo-d-gluconate production. Calcium 2-keto-l-gulonate was stable in the broth. Neither 2-keto-d-gluconic acid nor 5-keto-d-gluconic acid was detected in the final broth.
Collapse
Affiliation(s)
- T Sonoyama
- Department of Production, Shionogi and Company, Ltd., 192, Imafuku, Amagasaki, Hyogo 660, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Ennishi D, Asai H, Maeda Y, Shinagawa K, Ikeda K, Yokoyama M, Terui Y, Takeuchi K, Yoshino T, Matsuo K, Hatake K, Tanimoto M. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2010; 21:1217-1221. [DOI: 10.1093/annonc/mdp490] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
39
|
Hotta K, Kiura K, Takigawa N, Tabata M, Fujiwara Y, Tanimoto M. Progression-free survival (PFS) and overall survival (OS) in phase III trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7624] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Nogami N, Kiura K, Takigawa N, Harita S, Chikamori K, Shibayama T, Tabata M, Hotta K, Shinkai T, Tanimoto M. A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Fujiwara Y, Hotta K, Di Maio M, Kiura K, Takigawa N, Tabata M, Tanimoto M. Time trend in treatment-related deaths of patients with advanced non-small cell lung cancer enrolled into phase III trials of systemic treatment. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Ichihara E, Takigawa N, Hisamoto A, Hotta K, Tabata M, Kiura K, Tanimoto M. Chemotherapy for advanced non-small cell lung cancer with interstitial lung disease. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Kiura K, Tabata M, Takigawa N, Kuyama S, Segawa Y, Kamei H, Shibayama T, Hotta K, Matsuo K, Tanimoto M. A randomized phase III study of cisplatin and docetaxel with or without irinotecan in pts with advanced non-small cell lung cancer: Okayama Lung Cancer Study Group OLCSG 0403. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Gando Y, Kawano H, Yamamoto K, Sanada K, Tanimoto M, Oh T, Ohmori Y, Miyatani M, Usui C, Takahashi E, Tabata I, Higuchi M, Miyachi M. Age and cardiorespiratory fitness are associated with arterial stiffening and left ventricular remodelling. J Hum Hypertens 2009; 24:197-206. [DOI: 10.1038/jhh.2009.57] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
45
|
Gotoh H, Gohda T, Tanimoto M, Gotoh Y, Horikoshi S, Tomino Y. Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients. Nephrol Dial Transplant 2009; 24:3474-80. [DOI: 10.1093/ndt/gfp290] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Yonei Y, Fujiwara K, Maeda T, Tabata M, Tanimoto M. Comparison of incidence and pattern of interstitial lung disease (ILD) during erlotinib and gefitinib treatment in Japanese pts with NSCLC. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19056 Background: Erlotinib was approved in Dec 2007 in Japan, and incidence and pattern of ILD during its therapy for Japanese pts with NSCLC has not still been determined, although we had previously reported the frequency of ILD through the gefitinib treatment [PASCO2004, #7063]. In this study, we intended to elucidate this issue in pts receiving erlotinib therapy. Methods: We reviewed the clinical records of 159 pts who had initiated erlotinib therapy last year (cohort A), and of 330 pts receiving gefitinib between 2000 and 2003 (cohort B) for comparing the incidence and pattern of ILD during the both TKI treatments. Toxicity data during the first months after the initiation of TKIs were obtained. Results: The demographics of 489 pts were as follows; M:63%, Ad:75%, and PS 0–1:69%. None of pts in the cohort B received erlotinib therapy before the gefitinib treatment, whereas 66 of the 159 cohort A pts (42%) were given gefitinib before the erlotinib therapy. In 23% and 28% of the pts in the cohorts A and B, erlotinib and gefitinb treatments were discontinued within 1 month after the initiation of TKI therapy, respectively. Two pts (1.3%) developed ILD in the cohort A during the first month of erlotinib treatment, while 8 ILD-events (2.4%) were observed in the gefitinib therapy (cohort B) during the same treatment period. Both 2 pts who developed ILD during the erlotinib therapy had not had a history of prior gefitinib treatment. The toxicity grades of ILD were as follows: grades 1 and 2 in 1 each (cohort A) and grades 3, 4 and 5 in 1, 1 and 6 pts, respectively (cohort B). Statistically significant factors affecting the occurrence of ILD by multivariate analysis were presence of prior pulmonary fibrosis (OR=37.3, p<0.01) and poor PS (OR=6.4, p=0.02), but type of TKIs was not a significant risk factor for ILD. Conclusions: In this setting, the type of TKIs did not affect the incidence of ILD although its incidence after the initiation of erlotinib was somewhat low as compared with that during gefitinib therapy. In addition, the grade of ILD was less severe in the cohort A. These might be partly due to a patient selection based on the recent awareness of Japanese physicians regarding the risk factors for ILD events who learned it through the gefitinib treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Hotta
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - K. Kiura
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - N. Takigawa
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - H. Yoshioka
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - S. Harita
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - Y. Yonei
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - K. Fujiwara
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - T. Maeda
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - M. Tabata
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - M. Tanimoto
- Okayama Lung Cancer Study Group; Okayama University Hospital, Okayama, Japan; Kurashiki Central Hospital, Kurashiki, Japan; Chugoku Central Hospital, Fukuyama, Japan; NHO Okayama Medical Center, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| |
Collapse
|
47
|
Yoshioka H, Hayashi H, Kiura K, Takigawa N, Hotta K, Harita S, Kamei H, Bessho A, Tabata M, Tanimoto M. A phase II trial of erlotinib monotherapy in pretreated patients (pts) with non-small cell lung cancer (NSCLC) who do not possess active EGFR mutations. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8067 Background: Efficacy of gefitinib therapy strongly depends on the presence of active EGFR mutations in Asian NSCLC pts, with objective response rates (ORR) of 71.2% and only 1.1% in active mutant-positive (EGFRmt+) and -negative (EGFRmt-) tumors, respectively [Mok T, ESMO2008]. Recently, the survival advantage of erlotinib, another TKI, is observed even in pts with EGFRmt- tumors (HR=0.74, p=0.09 [Zhu C, JCO2008]), indicating such subpopulation might also benefit from this TKI. The aim of this trial was to evaluate its efficacy and toxicity in Japanese pts with relapsedEGFRmt- tumors. Methods: Primary endpoint was ORR. Patients with EGFRmt--NSCLC previously treated with one to three chemotherapy regimens were enrolled in this trial. The mutation status was assessed by the PCR clamp methods. Erlotinib was administered at a dose of 150mg/day until disease progression or unacceptable toxicities. Results: Thirty pts were enrolled between Jan and Dec 2008. Median duration of erlotinib treatment was 60 days. All pts were assessable for efficacy and safety. Demographics of the pts were as follows: M/F:24/6, Ad/others:20/10, ECOG-PS 0/1/2:7/19/4, and smoker/non-smoker:22/8. Platinum-based regimens were commonly used as the prior chemotherapy. Objective response was obtained in one pt (3.3%; RECIST). Seventeen pts obtained SD (56.7%). Toxicity profiles were almost tolerable with the treatment interruption in 11 pts (median duration; 10 days). Skin rash was common (grades 1, 2 and 3 in 7, 15, and 7 pts, respectively; NCI-CTCAE ver3). One pt developed grade 4 pulmonary embolism, but it seemed due to disease progression. Other 2 pts developed interstitial lung disease (grades 2 and 3 in one pt each). No treatment-related deaths (TRD) occurred. With a median follow-up time of 6.4 months, MST and MPFS time were 8.6 and 2.1 months, respectively. Conclusions: This is a first prospective biomarker study showing that erlotinib therapy for pretreated pts with EGFRmt- tumors seems as almost effective and safe as the standard docetaxel therapy (PR: 5.8%, SD: 42.7%, MST: 7.0 months, MTTP: 2.5 months and TRD: 4.9% [Shepherd JCO2000]). No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Yoshioka
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - H. Hayashi
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - K. Kiura
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - N. Takigawa
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - K. Hotta
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - S. Harita
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - H. Kamei
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - A. Bessho
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - M. Tabata
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| | - M. Tanimoto
- Kurashiki Central Hospital, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; Sumitomo Besshi Hospital, Niihama, Japan; NHO Iwakuni Medical Center, Iwakuni, Japan
| |
Collapse
|
48
|
Segawa Y, Hotta K, Takigawa N, Matsuo K, Yoshioka H, Hayashi H, Nogami N, Tabata M, Kiura K, Tanimoto M. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in pts with NSCLC previously treated with platinum-based chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) trial 0503. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8058 Background: Recent studies have demonstrated that docetaxel (DOC) monotherapy provides a significant survival prolongation in relapsed pts with NSCLC. However, its benefit remains modest and further improvement is needed. S-1 is a newly developed oral 5-fluorouracil derivative, possessing a promising anti-tumor activity in NSCLC. Based on a superior effect of combination of DOC and 5-fluorouracil derivative (capecitabine) to DOC alone in anthracycline-pretreated breast cancer pts, we conducted a randomized phase II study to evaluate the clinical significance of adding S-1 to DOC in the second-line setting. Methods: Pts with relapsed NSCLC to the first-line platinum-based chemotherapy were randomly allocated to DOC monotherapy (A arm; 60 mg/m2, day 1, q 3 wks) or a combination chemotherapy (B arm) of DOC (40 mg/m2, day 1, q 3 wks) and S-1 (80 mg/m2, days 1 to 15). The doses of arm B were determined based on the results of a phase I study conducted for Japanese pts with gastric cancer (Anticancer Res 24: 1843, 2004). The primary endpoint was response rate and secondary endpoints included OS, PFS and toxicity. Results: Between 2005 and 2008, 60 pts were enrolled (A/B: 29/31 pts). Demographics of the pts were as follows: M/F: 49/11, Ad/others: 40/20, ECOG-PS 0/1: 38/22. A median number of courses administered was 4 (range: 1 to 6). Objective response was obtained in 6 (20.7%) and 5 pts (16.1%) in arms A and B, respectively. With a median follow-up time of 16.9 months, MST and median PFST in arm A were longer than arm B (22.9 vs. 8.7 months and 3.7 vs. 3.4 months, respectively). The major toxicity was myelosuppression, with grade 4 neutropenia of 62% vs. 29%, whereas thrombocytopenia was generally mild. Grade 3 febrile neutropenia was observed in 4 and 1 pts, none of whom further developed grade 5 toxicity. Other grade 3 or greater non-hematological adverse events included fever (B: 1 pt), pneumonitis (B: 1 pt), liver dysfunction (B: 2 pts), skin rash (B: 1 pt), and all of them were improved with an appropriate supportive care. Conclusions: The trial suggests that docetaxel monotherapy remains a standard therapy for NSCLC pts who relapsed to platinum-based chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Segawa
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - K. Hotta
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - N. Takigawa
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - K. Matsuo
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - H. Yoshioka
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - H. Hayashi
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - N. Nogami
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - M. Tabata
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - K. Kiura
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| | - M. Tanimoto
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center, Nagoya, Japan; Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
49
|
Kuyama S, Segawa Y, Nogami N, Kiura K, Takigawa N, Shibayama T, Hosokawa S, Aoe K, Tabata M, Tanimoto M. A phase II trial of combination chemotherapy with irinotecan and amrubicin in pretreated patients with non-small cell lung cancer (NSCLC): Results of Okayama Lung Cancer Study Group Trial 0402. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19029 Background: We previously conducted a phase I trial of combination chemotherapy with irinotecan and amrubicin for NSCLC and found acceptable toxicity profiles with a favorable efficacy in patients with pretreated NSCLC. The aim of this phase II trial was to further evaluate its efficacy and toxicity in this population with a long-term follow-up. Methods: Primary endpoint was objective response. Patients with NSCLC previously treated with one or two chemotherapy regimens were enrolled in this trial. Irinotecan and amrubicin were both administered on days 1 and 8, every 3 weeks at doses of 100 and 40 mg/m2, respectively. Response and toxicity were assessed according to the RECIST guideline and NCI-CTC for AE v3.0. Results: Thirty-one pretreated NSCLC patients were enrolled between 2004 and 2006. A median number of courses administered was 3 (range: 1 to 6). All patients and courses were assessable for efficacy and safety. Demographics of the patients were as follows: M/F:21/10, Ad/others:21/10, ECOG-PS 0/1:12/19, and smoker/non-smoker:21/10. Platinum-based regimens were commonly used as the prior chemotherapy. Objective response was obtained in 9 of the 31 patients with a response rate of 29.0% (95%CI: 12.1–46.0%). Grade 4 leukopenia and neutropenia were observed in 6 (19%) and 14 (45%) patients, respectively, whereas thrombocytopenia were generally mild. Grade 3 febrile neutropenia was observed in 7 patients (23%), of whom two patients further developed Grade 4 and 5 septic shock each. Other grade 3 or greater non-hematological toxicities included diarrhea, vomiting, pneumonitis, liver dysfunction in 4, 1, 1 and 2 patients, respectively. With a median follow-up time of 24.2 months, median survival time and median progression-free survival time were 14.2 and 4.0 months, respectively. Conclusions: This combination seemed highly effective for pretreated NSCLC with an acceptable toxicity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Kuyama
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - Y. Segawa
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - N. Nogami
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - K. Kiura
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - N. Takigawa
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - T. Shibayama
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - S. Hosokawa
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - K. Aoe
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - M. Tabata
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | - M. Tanimoto
- Chugoku Central Hospital, Fukuyama, Japan; NHO Shikoku Cancer Center, Matsuyama, Japan; Okayama University Hospital, Okayama, Japan; NHO Minami-Okayama Medical Center, Okayama, Japan; Okayama Red Cross Hospital, Okayama, Japan; NHO Yamaguchi Ube Medical Center, Ube, Japan
| | | |
Collapse
|
50
|
Oze I, Kiura K, Hotta K, Ochi N, Fujiwara Y, Takigawa N, Tabata M, Shinkai T, Tanimoto M. Results of 27 years of phase III trials for patients with extensive-disease small-cell lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19021 Background: Few studies have formally assessed whether treatment outcomes for patients with extensive-disease small-cell lung cancer (ED-SCLC) enrolled in Phase III trials have improved substantially over the years. This investigation determined the trends in the outcomes for the patients in those trials. Methods: We analyzed trials that were reported between January 1991 and August 2008. Phase III randomized controlled trials were eligible if they compared first-line, systemic chemotherapy for ED-SCLC. Data were evaluated using linear regression analysis. Results: We identified 55 trials initiated between 1980 and 2006, involving 10,407 patients with 116 chemotherapy arms. The number of randomized patients and the proportions of patients with good performance status (PS) increased with the passage of time. In the 1990s, increasing numbers of studies examined cisplatin-based regimens, especially cisplatin and etoposide (PE) regimens, while decreasing numbers examined cyclophosphamide, doxorubicin, and vincristine-based regimens. A scattergram of the parameters ‘year of trial initiation’ and ‘median survival time’ (MST) indicated that MST increased 0.024 months (0.71 days) per year (P = 0.198). The multiple regression analysis showed no significant survival improvement over the years (regression coefficient for the year of trial initiation = 0.004, P = 0.980). In addition, the use of PE regimens did not prolong survival, whilst the proportion of good PS patients and the assignment of prophylactic cranial irradiation were significantly associated with favorable outcomes. Conclusions: The survival of patients with ED-SCLC enrolled in phase III trials has not improved significantly over the years, suggesting the need for a breakthrough, such as the discovery of novel molecular targets. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Oze
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| | - K. Kiura
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| | - K. Hotta
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| | - N. Ochi
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| | - Y. Fujiwara
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| | - N. Takigawa
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| | - M. Tabata
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| | - T. Shinkai
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| | - M. Tanimoto
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan
| |
Collapse
|